Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A
A BI-WEEKLY PUBLICATION FROM THE CEDARS-SINAI CHIEF OF STAFF July 20, 2012 Issue | Archived Issues

Physician news

- Daniel S. Berman, MD
- Victor Gura, MD
- Waguih William IsHak, MD
- Heather Jones, MD
- Chrisandra Shufelt, MD
- Allan W. Silberman, MD, PhD

» Read more


Meetings and events


Grand rounds

Click here to view upcoming Grand Rounds.


Upcoming CME conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - July 2012 (PDF)

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Restricted distribution programs required for bosentan, ambrisentan

June Pharmacy and Therapeutics decisions released

Due to the risk of teratogenicity associated with bosentan and ambrisentan, manufacturers of both drugs require that prescribers and patients be enrolled in restricted distribution programs. Please note that bosentan and ambrisentan are non-formulary at Cedars-Sinai.

If continuation of therapy is warranted for a patient who was on bosentan/ambrisentan prior to admission, please refer to the procedure outlined in the PDF below.

Bostentan Ambrisentan MD Fact Sheet - July 2012 (PDF)

In other pharmacy news, the June Pharmacy and Therapeutics Committee decisions and pertinent agenda topics are summarized in the PDF below. Highlights include: 2012 chest updates, anticoagulation protocol updates for dalteparin and enoxaparin, and 2012 empiric treatment guidelines for common adult and pediatric infections.

P&T Decisions - June 2012 (PDF)